Member Info for B2HS2L

Posted some of this last month:

The FDA can grant Orphan Drug Designation (ODD) for more than one indication for a drug, provided each indication is for a rare disease or condition affecting fewer than 200,000 people in the U.S.

SGC is not as prevalent as Soft Tissue Sarcoma in USA, so ODD application is a possibility .

Before phase two we select one indication, and we won't know before the end of p1b which that will be.

If Soft Tissue Sarcoma is not selected, and SGC is, then we will proceed with phase 2 without ODD advantages for Salivary Gland Cancer.

We need to make the company as valuable as possible before T/O by applying for ODD for SGC ASAP before any T/O discussion.

We did not give prior notice of application for ODD for STS, (Announced 05.09.2022), so I don't expect we will be so pre-warned if/when we do for SGC.

NR11 -

https://www.investopedia.com/terms/d/dark-pool.asp

A possibility, - I dunno.

Cj - wouldn't the intel be that two RNS's had been filed, narrowing the choice of subject matter.

A TR1 would concentrate minds in many boardrooms, as timing is key.

Each interested party pondering theirs after such an event.

Thanks Bigears1170

Anyone know what the headcount is at Coris.

Cast your minds back to this - (it's the first of a 2 para post, - cheers Nanomat):

"Nanomat

Posts: 102

Price: 37.25

Strong Buy

Trading pattern yesterday 5 Mar 2025 09:14

For the sake of accuracy I just want to point out that anyone with Level 2 would have seen that yesterday's continual fall in the SP was not due to so called 'MM manipulation'.

The facts are that there were a steady and continual number of significant lumpy sells that even accelerated in the afternoon.

So as MMs make their money on the spread they adjusted prices downwards to attract buyers.

That is what happened and if you do not have Level 2 you did not have the means of seeing this in real time yesterday.

So comments such as 'MM manipulation' is like commenting on how a football match was played without actually having seen the match itself!"

++++

I don't have level 2 access, so cannot corroborate, but assume the sells happened as stated.

Were the sellers referred to aware that news of the sale of Launch was imminent.

Selling this many shares implies the sellers were wealthy individuals, or many sellers colluding. The intent being to make money on the subsequent sp rise.

How much warning might they have had about this news.

This train of events might be repeated if Avacta has a leak.

Prion 25 -

Alan Ho, MD PhD, Chief of the Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center and member, Avacta Scientific Advisory Board, commented:

"We are very excited to move the development of AVA6000 to the next level to generate data that demonstrates clinically meaningful efficacy and durability of response in patients with previously treated salivary gland cancers. It is important to note the high degree of unmet need in this disease where few agents have shown efficacy. I am happy to participate in the trials of AVA6000 in this disease setting going forward."

Thus confirming that Memorial Sloan is where patients with previously treated salivary gland cancers are being treated.

He does not mention Breast Cancer or STS.

Lets wish him and his team well in delivering excellent results.

It might be that Avacta raised more money by selling the Dx companies separately.

The auction process referred to by Shaun Chilton could mean

1) There was a lot of interest from many companies for Launch, or perhaps Launch and Coris combined.

2) The disciplin of an auction with bids required by a certain date was a nod to the fact that best offers were required by a specific date, to augment funds for therapeutics development.

3) Management have known for a good few months now the likely value of the companies, and the timescale of available money generated.

4) £20 Million for both companies is not achievable if 'much smaller' when Coris is sold.

AVA6103

"The AVA6103 program has completed candidate selection and is in the pre-IND preparation stage with GMP manufacturing ongoing for the Phase 1 trial".

So in any takeover negotiation, this project management milestone has been completed, and thereby implying more value for AVA6103.

"The Company has seen a dramatic increase in therapeutic index in preclinical models, suggesting that AVA6103 could have an unprecedented safety profile in the clinic.

AVA6103 has the potential to treat hundreds of thousands of patients with the broad use of the topo I drug class and over 90% of solid tumors expressing FAP."

From EORTC Barcelona :

"The therapeutic index of exatecan is significantly increased by pre|CISION enabling, specifically the maximum tolerated dose of pre|CISION exatecan (AVA6103) observed is 75 times that of conventional exatecan in a daily dosing regimen"

75 trimes minimum now!

+++

I feel the timing of this news is significant as an attempt to buttress the sp after recent shenanigans.

It may have taken longer to chivy publish this news without the sp dip.

Is publication of RNS's other than 07:00 a two finger salute to those who would harm the sp?

To engage is to invite further FUD.

The Amigo's always ensure there are issues that can be brought forth to ensnare posters and cast doubt in minds.

One's backstop is the fable of the LFT.

I hear what they say, but I ignore it because it is a waste of time replying.

It's my time they waste if I respond, and I'm not willing to allow that to happen.

I would encourage posters not to engage.

It's tempting, but with time I learned how much time I wasted in responding.

Their aim is to spread FUD, not provide alternate opinions and points of view.

Amen to this. I shall not mention this again.

What's in it for anyone replying to permabear.

The responses are long, boring, and bearish.

He's convincing himself he's right, not taking a contrarian PoV.

Each of these posts should have a health warning, suggest

THE INFORMATION CONTAINED WITHIN THIS POST WILL ADVERESLY AFFECT YOUR MENTAL HEALTH.

+++

Don't engage.

Also

Brian Hahn appointed secretary not CFO vice James Heseltine.

I'm sure James is crunching numbers as he was before Brian's appointment.

From RNS 13.01.2025

"He received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.

"Brian brings the ideal combination of deep public company experience and understanding of the biotechnology sector that Avacta needs at this transformative stage," said Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta. "His strategic insight and track record of successful financial leadership in clinical-stage companies will be essential as we advance our promising pipeline and prepare for our next phase of growth, including our potential dual listing on the Nasdaq exchange."

"What drew me to Avacta was not just the company's innovative technology platforms. It also has a clear vision for revolutionizing cancer treatment through targeted therapies that improve outcomes for patients and their families," commented Brian Hahn. "The company has built a strong foundation with its pre|CISION® and Affimer® platforms, and I look forward to leveraging my experience to help accelerate Avacta's growth and strengthen its position in both the U.K. and U.S. capital markets."

+++

I dunno, but possibly not qualified to hold CFO position in UK a listed company.

Not hired for his maths skills, but for business acumen and potential NASDAQ listing.

Thanks gmcc

https://informaconnect.com/bioeurope-spring/presentation-information/

++++

Digital Presentation

Gain weeks of exposure and book more one-to-one meetings with a digital presentation.

Benefits of a digital presentation:

Increased exposure. Your virtual presentation can be viewed on-demand by attendees up to six weeks prior to the event, and throughout the conference.

++++

Seems like a great way to get more bang for your buck.

McMuff - "Either way the ongoing silence is EXTREMELY odd. Still can’t get my head round the abrupt change in CEO comms from November onwards. It’s so night and day different you’d actually think there had been a change in personnel in the role."

If we consider we are preparing to launch on NASDAQ, wouldn't that kind of comms be frowned upon on this exchange, so

CC acted accordingly.

However this makes the reports of SC / CC interaction with Telegram the more concerning.

Waiting since January for a nothing response is problematic.

It hasn't addressed the subject, it just told you what they can't discuss.

Anyone else had a response using the same wording.

I asked them if Avacta had a crown jewels defence for the company.

Can't imagine what that response is going to sound like.

Christ alive - is that the time, - must dash I've been double parked all morning.

Https://www.genomeweb.com/cancer/tempus-q4-revenues-36-percent-pronounced-growth-hereditary-screening-mrd-businesses

Tempus Q4 Revenues up 36 Percent With 'Pronounced Growth' in Hereditary Screening, MRD Businesses

Feb 25, 2025

NEW YORK – Despite missing the consensus Wall Street revenue estimate, Tempus AI saw its main businesses "firing on all cylinders" in Q4 2024 as revenues rose 36 percent year over year, the company said on Monday.

The Chicago-based firm reported after the close of the market that for the quarter ended Dec. 31, 2024, its revenues rose to $200.7 million from $147.7 million in Q4 2023, missing analysts' average estimate of $202.8 million. The company's genomics business generated $120.4 million in revenue, up 31 percent from $92.2 million in Q4 2023, and the data and services business generated $80.2 million in revenue, an increase of 45 percent from $55.5 million in the year-ago quarter.

According to a letter to investors from Tempus CEO Eric Lefkofsky and CFO Jim Rogers, the company ran approximately 72,500 next-generation sequencing-based tests in Q4 2024, up from 59,200 in Q4 2023. Unit growth in the genomics business picked up through the last half of the year "as our sales force found its 'sea legs,' which we believe sets us up well for the coming year," they wrote.

***They added that the business saw consistent growth in solid tumor profiling and liquid biopsies, as well as "even more pronounced growth" in the hereditary screening and minimal residual disease businesses.***

Only the first few paragraph's quoted, but I think Avacta has become a gold card holder.

Https://www.lse.co.uk/share-prices/sectors/medicine-and-biotech/

Medicine and Biotech Sector Fallers

Avacta sp not alone in this list.

Time for another one of these Christina, - for prospective partners of future enterprise, as well as share holders.

Note the date, it ain't today !! !

19 Jun 2023 07:00

RNS Number : 1168D

Avacta Group PLC

19 June 2023

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Statement regarding market speculation

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, notes the recent market speculation regarding a possible fundraising.

The Company regularly considers potential funding opportunities, both non-dilutive and dilutive, to ensure its business operations remain well financed and the best interests of its stakeholders are maintained. While this includes maintaining a dialogue with both current shareholders and other potential investors, no fundraising is imminent.

Avacta has a strong cash balance of £27 million on its balance sheet as at 31 May (unaudited) and anticipates strong news flow in the coming months from across the Group. The Therapeutics division of the Company continues to make good progress in the Phase 1 clinical trial of AVA6000, its lead pre|CISIONTM targeted chemotherapy.....

-Ends- except:

Can we have the next CLN payment in cash please, - asking for many friends here.

I hope you sent a copy to Peel Hunt the NOMAD.

Coughlin's predecessor also connected with the Telegram group.

https://x.com/SarahJean191/status/1717536397416869977